Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -56.68% is 27% above its 5-year average of -77.94%, near the low end of its 5-year range (-201.77%–370.24%).
18.39% above its 12-month average of -69.45%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -74.00%.
NET PROFIT MARGIN
-56.68%
NET PROFIT MARGIN AVG TTM
-69.45%
NET PROFIT MARGIN AVG 3Y
-80.53%
NET PROFIT MARGIN AVG 5Y
-77.94%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+18.39%
CURRENT VS 3Y AVG
+29.62%
CURRENT VS 5Y AVG
+27.27%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 749 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
908 Devices Inc.
Market Cap
$507.72M
Net Profit Margin
-56.68%
TTM Avg
-69.45%
3Y Avg
-80.53%
5Y Avg
-77.94%
Market Cap
$501.13M
Net Profit Margin
-3566.68%
TTM Avg
-585431.82%
3Y Avg
-433391.80%
5Y Avg
-288954.46%
Market Cap
$517.30M
Net Profit Margin
-296000.00%
TTM Avg
-345077.99%
3Y Avg
-146585.06%
5Y Avg
-98190.17%
Market Cap
$513.04M
Net Profit Margin
-1371.51%
TTM Avg
-709.80%
3Y Avg
-108166.39%
5Y Avg
-73106.10%
Market Cap
$495.50M
Net Profit Margin
-10.85%
TTM Avg
-18.16%
3Y Avg
-29.23%
5Y Avg
-75.36%
Market Cap
$495.09M
Net Profit Margin
-32724.20%
TTM Avg
-6251.97%
3Y Avg
-3125.99%
5Y Avg
-2083.99%
Market Cap
$523.60M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$528.87M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$486.60M
Net Profit Margin
11.55%
TTM Avg
13.38%
3Y Avg
8.98%
5Y Avg
-0.37%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 908 Devices Inc. (MASS) | $507.72M | -56.68% | -69.45% | -80.53% | -77.94% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $501.13M | -3566.68% | -585431.82% | -433391.80% | -288954.46% |
| Altimmune, Inc. (ALT)vs › | $517.30M | -296000.00% | -345077.99% | -146585.06% | -98190.17% |
| Crescent Biopharma, Inc. (CBIO)vs › | $513.04M | -1371.51% | -709.80% | -108166.39% | -73106.10% |
| Evolus, Inc. (EOLS)vs › | $495.50M | -10.85% | -18.16% | -29.23% | -75.36% |
| Oculis Holding AG (OCS)vs › | $495.09M | -32724.20% | -6251.97% | -3125.99% | -2083.99% |
| Monopar Therapeutics Inc. (MNPR)vs › | $523.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Immix Biopharma, Inc. (IMMX)vs › | $528.87M | 0.00% | 0.00% | 0.00% | 0.00% |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.60M | 11.55% | 13.38% | 8.98% | -0.37% |
| ProKidney Corp. (PROK)vs › | $532.96M | -10599.76% | -44116.54% | -22058.27% | -14705.51% |
Operating Margin
-46.0%
Net Profit Margin
-56.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -74.00% |
| 2026-03-31 | -89.34% |
| 2025-12-31 | 24.61% |
| 2025-09-30 | -106.46% |
| 2025-06-30 | -102.08% |
| 2025-03-31 | 370.24% |
| 2024-12-31 | -103.33% |
| 2024-09-30 | -201.77% |
| 2024-06-30 | -109.47% |
| 2024-03-31 | -147.09% |
| 2023-12-31 | -51.77% |
| 2023-09-30 | -49.61% |
| 2023-06-30 | -77.28% |
| 2023-03-31 | -132.10% |
| 2022-12-31 | -84.09% |
| 2022-09-30 | -39.62% |
| 2022-06-30 | -72.92% |
| 2022-03-31 | -113.35% |
| 2021-12-31 | -21.87% |
| 2021-09-30 | -41.33% |
| 2021-06-30 | -89.69% |
| 2021-03-31 | -109.96% |
| 2020-12-31 | -178.87% |
| 2020-09-30 | -28.47% |
| 2020-06-30 | 18.83% |
| 2020-03-31 | -74.13% |
| 2019-12-31 | -5.86% |
| 2019-09-30 | -139.61% |
| 2019-06-30 | -130.05% |
| 2019-03-31 | -131.95% |
